Keywords: AstraZeneca, Bristol-Myers Squibb, Komoglyze, Saxagliptin, Type 1 and 2 diabtes, Novo Nordisk, Levemir, Victoza, Faslodex, Breast cancer, Japan, CHMP, Europe
Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan
Article | 26 September 2011
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
